International Patent: COMPOSITIONS AND METHODS FOR DIRECTLY OR INDIRECTLY INHIBITING TUMOR NECROSIS FACTOR (TNF) AND ACTIVATING A GLP-1 RECEPTOR IN A CELL

GENEVA, Sept. 24 -- ELANGEN, INC. filed a patent application (US2026/020213) for “COMPOSITIONS AND METHODS FOR DIRECTLY OR INDIRECTLY INHIBITING TUMOR NECROSIS FACTOR (TNF) AND ACTIVATING A GLP-1 RECEPTOR IN A CELL”. With publication no. WO/2026/198941, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: A61K 47/68

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....